NanoCelle™ is a mouth spray delivery system targeting cannabis-based medicines.
() has received preliminary results from research underway that is reviewing its patented delivery platform, NanoCelle™.
NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™.
The research has concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.
The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.
READ: Medlab Clinical advances research amid nutraceuticals revenue growth
Medlab’s CEO Dr Sean Hall said: “These results provide a significant level of confidence in Medlab’s NanoCelle™ platform and further confirms specific proposed functions for Medlab’s cannabis medicines.
“These results in conjunction with the early positive feedback from doctors prescribing NanaBis™ under the TGA’s Special Access Scheme, gives Medlab great confidence in its NanoCelle™ research.”
The Special Access Scheme allows Medlab to supply NanaBis™, with NanoCelle™, to prescribing doctors.
Research conducted by University of Sydney
The research is being conducted by the University of Sydney’s Nano Institute, School of Pharmacy.
The difference between Medlab's two cannabis-based medicines, NanaBis™ and NanaBidial™, is their formulation of tetrahydrocannabinol (THC) and cannabidiol (CBD).
NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.
